151 completed, 19 active not recruiting, 11 terminated, 9 unknown. 207 Phase 3, 15 Phase 2.
Follow Spondylarthritis: new trials by email Literature Review of Spondylarthritis trials Research Report on Spondylarthritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) Placebo, Zasocitinib - Psoriatic Arthritis | Phase 3 | Not yet recruiting | Takeda | 644 | 2027-01-11 | 2026-10-27 |
| Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers Deucravacitinib - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 3 | Not yet recruiting | Bristol-Myers Squibb | 2300 | 2026-12-31 | 2026-09-03 |
| Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis Zasocitinib - Psoriatic Arthritis | Phase 3 | Recruiting | Takeda | 1182 | 2026-03-11 | 2026-11-12 |
| A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA) 608, Placebo - Axial Spondyloarthritis, Non-Radiographic | Phase 3 | Not yet recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 380 | 2026-03-09 | 2026-01-16 |
| Efficacy and Safety of Xeligekimab in the Treatment of Non-Radiographic Axial Spondyloarthritis Xeligekimab injection - Nr-axial Spondyloarthritis, Non-Radiographical Axial Spondyloarthritis | Phase 2 / Phase 3 | Not yet recruiting | Lingli Dong | 40 | 2026-01-31 | 2026-01-14 |
| A Study of Picankibart in Patients With Active Psoriatic Arthritis Placebo, Picankibart - Psoriatic Arthritis | Phase 2 / Phase 3 | Recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 222 | 2025-12-18 | 2026-03-20 |
| A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis Sonelokimab - Arthritis, Psoriatic | Phase 3 | Enrolling by invitation | MoonLake Immunotherapeutics AG | 1560 | 2025-11-13 | 2026-11-12 |
| A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) 608 dose, Placebo - Ankylosing Spondylitis | Phase 3 | Recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 500 | 2025-11-07 | 2025-12-10 |
| A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis LNK01001, Placebo - Ankylosing Spondylitis | Phase 3 | Recruiting | Lynk Pharmaceuticals Co., Ltd | 352 | 2025-08-29 | 2026-11-12 |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines Zasocitinib, Placebo - Psoriatic Arthritis | Phase 3 | Active not recruiting | Takeda | 601 | 2025-03-10 | 2026-10-14 |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines Zasocitinib, Active Comparator, Placebo - Psoriatic Arthritis | Phase 3 | Active not recruiting | Takeda | 1583 | 2025-03-03 | 2026-11-12 |
| A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis Icotrokinra, Placebo, Active reference comparator - Arthritis, Psoriatic | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 552 | 2025-02-21 | 2026-11-03 |
| A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis Icotrokinra, Placebo - Arthritis, Psoriatic | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 813 | 2025-01-09 | 2026-11-03 |
| A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis SHR-1314 injection, Placebo - Psoriatic Arthritis | Phase 3 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 208 | 2024-11-04 | 2026-08-06 |
| A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants Guselkumab - Crohns Disease, Colitis, Ulcerative | Phase 3 | Recruiting | Janssen Research & Development, LLC | 196 | 2024-10-29 | 2026-11-03 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis Bimekizumab, Risankizumab, Placebo - Psoriatic Arthritis | Phase 3 | Completed | UCB Biopharma SRL | 553 | 2024-10-21 | 2026-09-02 |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug Sonelokimab, Placebo - Arthritis, Psoriatic | Phase 3 | Active not recruiting | MoonLake Immunotherapeutics AG | 960 | 2024-10-15 | 2026-11-16 |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response Sonelokimab, Placebo, Risankizumab - Arthritis, Psoriatic | Phase 3 | Active not recruiting | MoonLake Immunotherapeutics AG | 600 | 2024-10-15 | 2026-11-16 |
| Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight Ixekizumab, Tirzepatide - Psoriatic Arthritis, Obesity | Phase 3 | Completed | Eli Lilly and Company | 279 | 2024-09-24 | 2026-05-13 |
| A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis bimekizumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis | Phase 3 | Active not recruiting | UCB Biopharma SRL | 89 | 2024-07-29 | 2026-07-17 |
Showing 20 of 207. Sign in to see all of them.
Arthritis, Psoriatic (105) · Spondylitis, Ankylosing (82) · Axial Spondyloarthritis (26) · Psoriasis (23) · Arthritis (18) · Spondylarthropathies (12) · Non-Radiographic Axial Spondyloarthritis (10) · Arthritis, Rheumatoid (6) · Arthritis, Juvenile (5) · Spondylitis (5) · Inflammation (4) · Joint Diseases (4) · Musculoskeletal Diseases (4) · Skin Diseases (4)
Bone Diseases (206) · Joint Diseases (203) · Musculoskeletal Diseases (203) · Spinal Diseases (203) · Spondylitis (202) · Spondylarthropathies (193) · Arthritis (189) · Skin and Connective Tissue Diseases (110) · Skin Diseases, Papulosquamous (105) · Skin Diseases (101) · Ankylosis (99) · Psoriasis (82) · Axial Spondyloarthritis (74) · Immune System Diseases (13)
secukinumab (29) · Adalimumab (25) · golimumab (14) · Etanercept (13) · Methotrexate (11) · bimekizumab (11) · ixekizumab (11) · Ustekinumab (10) · apremilast (10) · Infliximab (9) · tofacitinib (9) · guselkumab (7) · Certolizumab Pegol (5) · GLPG0634 (5) · risankizumab (5)
Novartis Pharmaceuticals (27) · Janssen Research & Development, LLC (14) · Amgen (11) · UCB Biopharma SRL (11) · Eli Lilly and Company (10) · Pfizer (9) · Abbott (8) · AbbVie (7) · Centocor, Inc. (6) · Biocad (4) · Bristol-Myers Squibb (4) · Gilead Sciences (4) · Merck Sharp & Dohme LLC (4) · Takeda (4) · UCB BIOSCIENCES GmbH (4)
United States (103) · Germany (88) · Poland (85) · Czechia (78) · Spain (77) · United Kingdom (75) · Canada (72) · Russia (69) · Hungary (62) · France (59) · Belgium (55) · Australia (53) · Bulgaria (50) · Italy (50) · China (42)
Beverly Paperiello (3) · Roman Ivanov, PhD (3)
PMID 31203228, PMID 38446397, PMID 37316690, PMID 40194794, PMID 41807031, PMID 41965705, PMID 42386286, PMID 34618347, PMID 35305260, PMID 38488975, PMID 39120849, PMID 33722947, PMID 34795065, PMID 36792107, PMID 39120848, PMID 40241921, PMID 30018799, PMID 30473179, PMID 31077258, PMID 31112005, PMID 31909868, PMID 31964419, PMID 32006348, PMID 32352653, PMID 32816215, PMID 33227175, PMID 33351179, PMID 34536218, PMID 34773130, PMID 34870800, PMID 35393269, PMID 35429281, PMID 36282526, PMID 36526796, PMID 36642439, PMID 36931693, PMID 36958766, PMID 36995469, PMID 37906417, PMID 37982966, PMID 38488976, PMID 38683479, PMID 38754125, PMID 39215949, PMID 39534481, PMID 39624020, PMID 40347389, PMID 40694276, PMID 40875187, PMID 41039829
2015 (12), 2023 (11), 2009 (10), 2016 (9), 2014 (6), 2017 (6), 2019 (6), 2018 (5), 2008 (1), 2025 (1), R21AR053646 (1)